Ye Weiguo's Form 4 filing
Gyre Therapeutics, Inc. (GYRE) · filed May 22, 2026
- Accession no.
- 0001140361-26-022642
- Filed
- May 22, 2026
- Trade date
- May 20-21, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $136.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ye WeiguoCIK 0001985496 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 20, 2026 | Common Stock | MOption exerciseAcquired | +9,400 | $0.75 | +$7,050 | 709,400 | Direct | |
| May 20, 2026 | Common Stock | SSaleDisposed | −9,400 | $6.15F1 | −$57,810 | 700,000 | Direct | |
| May 21, 2026 | Common Stock | MOption exerciseAcquired | +12,820 | $0.75 | +$9,615 | 712,820 | Direct | |
| May 21, 2026 | Common Stock | SSaleDisposed | −12,820 | $6.15F2 | −$78,843 | 700,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 20, 2026 | Common Stock | MOption exerciseDisposed | −9,400 | $0.00 | $0 | 917,715 | Direct | |
| May 21, 2026 | Common Stock | MOption exerciseDisposed | −12,820 | $0.00 | $0 | 904,895 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.0908 to $6.2935. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.05 to $6.22. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.